Objective. To investigate the features of the course, clinical manifestations and the effect of symptomatic slow anti-inflammatory drugs (SYSADOA) on the course of the disease in patients with low back pain and low bone mineral density.
Materials and methods. The study included 100 patients (60 women and 40 men) aged 34 to 80 years. Patients were divided into 3 groups depending on the index of bone mineral density (BMD). Peculiarities of the course and effectiveness of treatment were assessed using questionnaires VAS, Oswestry, Roland-Morris and McGill. Levels of nonspecific indicators of inflammation (ESR and CRP), cytokines (IL-1, IGF-1, NO), metabolic indicators (lipid, carbohydrate, liver markers) were also studied. “SPSS Statistics” software was used for statistical data processing.
Results. The research showed that patients with low bone mineral density had worse performance results on the VAS, Oswestry, McGill and Roland-Morris questionnaires compared to patients with normal BMD. Inflammatory rates such as ESR, CRP, IL-1, NO, IGF-1 were also worse in patients with low bone mineral density. The dynamics of questionnaires and inflammatory markers during treatment was better in patients with normal BMD.
Conclusions. Our study showed that patients with low bone mineral density had a more severe course of low back pain: more intense inflammation, worse psycho-emotional state, physical activity and quality of life compared to people with normal BMD. Moreover, patients with low bone mineral density had worse dynamics of SYSADOA treatment.